Targets › RPOBC
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.
Open in Phaseline: the race on RPOBC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ANRS, Emerging Infectious Diseases | Linezolid Bacterial 70S ribosome inhibitor | RPOBC | Phase 3 | Tuberculous Meningitis | – |
Tuberculous Meningitis (1)
small molecule (1)
ANRS, Emerging Infectious Diseases (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.